Apellis: Raymond James Maintains Outperform, PT Down to $50

Apellis: Raymond James Maintains Outperform, PT Down to $50

Raymond James has maintained its outperform rating for Apellis Pharmaceuticals (APLS) but has lowered its target price from $46 to $50. The update reflects the analysts' assessment of the company's performance and future prospects.

According to Raymond James, the company's recent financial results and market conditions have led to a downward revision in the target price. Despite the change, the firm remains optimistic about Apellis' potential for growth and innovation in the pharmaceutical sector.

The latest update follows a series of changes in analyst ratings and price targets for various U.S.-listed companies. On Tuesday, several securities analysts revised their ratings and price targets for companies such as Blackline, Cadence Design Systems, and Coinbase Global [1].

For investors and financial professionals, this update serves as a reminder to stay informed about changes in analyst ratings and target prices, as they can significantly impact investment decisions. The neutral and objective tone of the update ensures that investors can make informed decisions based on the latest information.

References:

[1] https://www.tradingview.com/news/reuters.com,2025:newsml_L4N3TQ0GZ:0-blackline-cadence-design-systems-coinbase-global/